Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOkamura, Nobuyukien
dc.contributor.authorVillemagne, Victor Len
dc.contributor.authorDrago, Johnen
dc.contributor.authorPejoska, Svetlanaen
dc.contributor.authorDhamija, Rajinder Ken
dc.contributor.authorMulligan, Rachel Sen
dc.contributor.authorEllis, Julia Ren
dc.contributor.authorAckermann, Uween
dc.contributor.authorO'Keefe, Graeme Jen
dc.contributor.authorJones, Garethen
dc.contributor.authorKung, Hank Fen
dc.contributor.authorPontecorvo, Michael Jen
dc.contributor.authorSkovronsky, Danielen
dc.contributor.authorRowe, Christopher Cen
dc.identifier.citationJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2010; 51(2): 223-8en
dc.description.abstractPET provides a noninvasive means to evaluate the functional integrity of the presynaptic monoaminergic system in the living human brain.In this study, a novel (18)F-labeled tetrabenazine derivative, (18)F-(+)fluoropropyldihydrotetrabenazine ((18)F-AV-133), was used for the noninvasive assessment of the vesicular monoamine transporters type 2 (VMAT2) in 17 Parkinson disease (PD) patients and 6 healthy controls. The binding potential (BP) of (18)F-AV-133 was calculated using Logan graphical analysis. Voxel-based and volume-of-interest-based analyses of BP images were performed to examine brain regional reductions in VMAT2 density in PD.VMAT2 BP was decreased by 81% in the posterior putamen, 70% in the anterior putamen, and 48% in the caudate nucleus of PD patients. Voxel-based analysis demonstrated VMAT2 reductions in the striatum and mid brain of PD patients. Furthermore, VMAT2 BPs in the caudate nuclei significantly correlated with the clinical severity of PD.These findings indicate that the novel (18)F-labeled ligand (18)F-AV-133 can sensitively detect monoaminergic terminal reductions in PD patients. Studies with (18)F-AV-133 may allow the presymptomatic identification of individuals with disorders characterized by degeneration of dopaminergic nigrostriatal afferents.en
dc.subject.otherBrain.metabolism.radionuclide imagingen
dc.subject.otherCase-Control Studiesen
dc.subject.otherCaudate Nucleus.metabolism.radionuclide imagingen
dc.subject.otherCorpus Striatum.metabolism.radionuclide imagingen
dc.subject.otherDopamine Plasma Membrane Transport Proteins.metabolismen
dc.subject.otherFluorine Radioisotopes.diagnostic useen
dc.subject.otherMiddle Ageden
dc.subject.otherParkinson Disease.metabolism.physiopathology.radionuclide imagingen
dc.subject.otherPositron-Emission Tomographyen
dc.subject.otherPutamen.metabolism.radionuclide imagingen
dc.subject.otherRadiopharmaceuticals.diagnostic useen
dc.subject.otherTetrabenazine.analogs & derivatives.diagnostic useen
dc.subject.otherTissue Distributionen
dc.subject.otherVesicular Monoamine Transport Proteins.metabolismen
dc.titleIn vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Nuclear Medicineen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australiaen
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.